Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional)

0
5

Funding Opportunity ID:334577
Opportunity Number:RFA-CA-21-021
Opportunity Title:Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Education
Health
Category Explanation:
CFDA Number(s):93.393
Eligible Applicants:State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Jul 06, 2021
Close Date:Oct 06, 2021
Last Updated Date:Jul 06, 2021
Award Ceiling:$850,000
Award Floor:$0
Estimated Total Program Funding:
Expected Number of Awards:
Description:The National Cancer Institute (NCI) invites research grant proposals for transdisciplinary studies that will enhance our knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation and increased cancer risk. Through this Funding Opportunity Announcement (FOA), the Metabolic Dysregulation and Cancer Risk Program will focus on metabolic dysregulation as the key process linking obesity with cancer risk. For the purpose of this FOA, metabolic dysregulation is defined as alterations in glucose utilization and storage, insulin sensitivity, and/or lipid metabolism. Proposals should specifically seek to advance our understanding of how metabolic dysregulation in individuals affects cancer risk and identify mechanisms that will enhance (i) cancer risk prediction, (ii) screening for high-risk individuals in clinical settings, and (iii) identification of potential targets for preventive and therapeutic interventions. This FOA is published in parallel with RFA-CA-21-022 Coordinating Center for the Metabolic Dysregulation and Cancer Risk Program: a Transdisciplinary Approach to Obesity-associated Research (U24 Clinical Trial Not Allowed). The individual research grants and the Coordinating Center funded under these FOAs together will constitute the Metabolic Dysregulation and Cancer Risk Program.
Version:1





Visit the Official Webpage For More Details on Metabolic Dysregulation and Cancer Risk Program, Research Grants: a Transdisciplinary Approach to Obesity-Associated Research (U01 Clinical Trial Optional)

LEAVE A REPLY

Please enter your comment!
Please enter your name here